Active Ingredient History
Givinostat (INN) or gavinostat is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominoplasty (Phase 2)
Arthritis, Juvenile (Phase 2)
Crohn Disease (Phase 1/Phase 2)
Hodgkin Disease (Phase 1/Phase 2)
Immunoglobulin D (Phase 2)
Inflammation (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Multiple Myeloma (Phase 2)
Muscular Dystrophy, Duchenne (Phase 3)
Myeloproliferative Disorders (Phase 2)
Polycythemia Vera (Phase 2)
Receptors, Tumor Necrosis Factor (Phase 2)
Schnitzler Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue